circadian rhythm raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-07-03 and is reviewed periodically as new material appears.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
With the goal of mitigating these disadvantages while applying nanotechnology to electronics, researchers at the National Science Foundation's Nanoscale Science and Engineering Center for High-Rate Nanomanufacturing (CHN) at Northeastern University with partners UMass Lowell and University of New Hampshire have developed a directed assembly process of single-walled carbon nano tube (SWNT) networks to create a circuit template that can be transfer from one substrate to another.
Salyut 1, the first space station, was launched by the Soviets on April 19, 1971. Three days later, the Soyuz 10 crew attempted to dock with it, but failed to achieve a secure enough connection to safely enter the station. The Soyuz 11 crew of Vladislav Volkov, Georgi Dobrovolski and Viktor Patsayev successfully docked on June 7, and completed a then record 22-day stay. The crew became the second in-flight space fatality during their reentry on June 30, when they were asphyxiated due to the spacecraft's cabin becoming depressurized, shortly after undocking. The disaster was blamed on a faulty cabin pressure valve, that allowed the air to vent into space. The crew was not wearing pressure suits and had no chance of survival once the leak occurred. To prevent a recurrence of the Soyuz 11 tragedy, Soviet engineers redesigned the Soyuz spacecraft and mandated that cosmonauts wear Sokol pressure suits during launch and landing, a requirement still in place today. The United States launched a single orbital workstation, Skylab, on May 14, 1973. It was launched using a leftover Saturn-5 rocket from the Apollo programme. Skylab weighed 169,950 pounds (77,090 kg), was 58 feet (18 m) long by 21.7 feet (6.6 m) in diameter, and had a habitable volume of over 10,000 cubic feet (280 m3). Skylab was damaged during the ascent to orbit, losing one of its solar panels and a meteoroid thermal shield. Subsequent crewed missions repaired the station, and conducted valuable research.
Kashmir, a Himalayan region at the northern tip of the Indian subcontinent, was governed as the autonomous princely state of Jammu and Kashmir during the British Raj before the Partition of India in August 1947. This sparked a major territorial dispute between India and Pakistan, resulting in several conflicts over the region. India controls about 45.1% of Kashmir, including Jammu and Kashmir and Ladakh, while Pakistan controls roughly 38.2%, comprising Azad Jammu and Kashmir and Gilgit−Baltistan. Additionally, about 20% of the region, known as Aksai Chin and the Shaksgam Valley, is under Chinese control. India claims the entire Kashmir region based on the Instrument of Accession signed by the princely state's ruler, Maharaja Hari Singh, while Pakistan argues for its Muslim-majority population, and geographical proximity to Pakistan. The United Nations was involved in resolving the conflict, leading to a ceasefire in 1949 and the establishment of the Line of Control (LoC) as a de facto border. India, fearing Kashmir's secession, did not hold the promised plebiscite, as it believed Kashmiris would vote to join Pakistan. Pakistan claims that its position is for the right of the Kashmiri people to determine their future through impartial elections as mandated by the United Nations, while India has stated that Kashmir is an "integral part" of India, referring to the 1972 Simla Agreement and to the fact that regional elections take place regularly. Certain Kashmiri independence groups believe that Kashmir should be independent of both India and Pakistan.
== History == Setipiprant was initially researched by Actelion as a treatment for allergies and inflammatory disorders, particularly asthma, but despite being well tolerated in clinical trials and showing reasonable efficacy against allergen-induced airway responses in asthmatic patients, it failed to show sufficient advantages over existing drugs and was discontinued from further development in this application. However, following the discovery in 2012 that the prostaglandin D2 receptor (DP/PGD2) is expressed at high levels in the scalp of men affected by male pattern baldness, the rights to setipiprant were acquired by Kythera to develop the drug as a novel treatment for baldness. The favorable pharmacokinetics and relative lack of side effects seen in earlier clinical trials mean that fresh clinical trials for this new application can be conducted fairly quickly. As of 2015, setipiprant is currently under development by Allergan for the prevention of androgenic alopecia after their successful acquisition of Kythera.
Evidence for the important role antithrombin plays in regulating normal blood coagulation is demonstrated by the correlation between inherited or acquired antithrombin deficiencies and an increased risk of any affected individual developing thrombotic disease. Antithrombin deficiency generally comes to light when a patient suffers recurrent venous thrombosis and pulmonary embolism.
Sources: en.wikipedia.org
== Metabolism == The two bioactive forms of vitamin B12 are methylcobalamin in cytosol and adenosylcobalamin in mitochondria. The cyanide is converted to thiocyanate and excreted by the kidney. The MMACHC gene product catalyzes the decyanation of cyanocobalamin as well as the dealkylation of alkylcobalamins including methylcobalamin and adenosylcobalamin. The MMACHC gene product is characterised as a cyanocobalamin reductase (cyanide-eliminating) and an alkylcobalamin reductase. It enables the interconversion of cyano- and alkylcobalamins. Endogenous vitamin B12 becomes inactive when exposed to hydrogen cyanide and nitric oxide in cigarette smoke. More specifically, it causes the active forms to convert to cyanocobalamin, causing a functional deficiency. Functional vitamin B12 deficiency can also develop with heavy regular use of nitrous oxide N2O, also known as "laughing gas", by oxidizing the cobalt atom and inactivating the vitamin. Used for anaesthesia in a clinical setting or as a propellant gas, it's commonly abused as a recreational drug. The enzymes that use B12 as a built-in cofactor are methylmalonyl-CoA mutase (PDB 4REQ) and methionine synthase (PDB 1Q8J).
== Mechanism of action == Normally, upon injury to the endothelium, collagen mediated GPVI signalling increases platelet formation by thromboxane A2, therefore creating a blood clot. In case of blood vessel damage, collagen on the extracellular matrix is exposed. As platelets interact with it, an activation signal is sent for aggregation. Platelets interact indirectly with collagen, via the von Willebrand Factor (vWF), which connects the collagen to the platelet GPIb receptor, forcing them close to the site of vessel damage. There, they can interact with receptors on the extracellular matrix, which stimulate adhesion through integrins (heterodimer α2β1), and downstream signalling. GPVI is present as a complex with the Fc receptor (FcR) γ-chain, which gets phosphorylated by SYK as a result of activation by a stimulus. This generates a downstream signal, leading to platelet activation. While this is important in case of injury, inappropriate activation of platelets can lead to the formation of clots within the circulation. Such is the case with Convulxin, which can induce a signalling cascade similar to that of collagen. Due to its high affinity, convulxin bind to GPVI and causes clustering of the glycoproteins. Research has proved that GPlb is not involved in convulxin-induced activation, but that the p62/GPVI collagen receptor is the unique binding site, and protein phosphorylation happens more rapidly and more intensely than in the case of collagen.
More generally, El Niño can affect commodity prices and the macroeconomy of different countries. It can constrain the supply of rain-driven agricultural commodities; reduce agricultural output, construction, and services activities; increase food prices; and may trigger social unrest in commodity-dependent poor countries that primarily rely on imported food. A 2014 University of Cambridge Working Paper shows that while Australia, Chile, Indonesia, India, Japan, New Zealand and South Africa face a short-lived fall in economic activity in response to an El Niño shock, other countries may actually benefit from an El Niño weather shock (either directly or indirectly through positive spillovers from major trading partners), for instance, Argentina, Canada, Mexico and the United States. Most countries experience short-run inflationary pressures following an El Niño shock, while global energy and non-fuel commodity prices increase. The IMF has traced El Niño events to macroeconomic performance. In a one-year time horizon, an El Niño shock is associated with changes in real GDP growth of -1.01% in Indonesia, -0.72% in South Africa, +0.5% in the United States, +1.57% in Mexico, and +1.81% in Thailand.
210Po is an alpha emitter that has a half-life of 138.376 days; it decays directly to stable 206Pb. The majority of the time, 210Po decays by emission of an alpha particle only, not by emission of an alpha particle and a gamma ray; about one in 100,000 decays results in the emission of a gamma ray.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.